398 related articles for article (PubMed ID: 27902902)
1. History of the First-Generation Marek's Disease Vaccines: The Science and Little-Known Facts.
Schat KA
Avian Dis; 2016 Dec; 60(4):715-724. PubMed ID: 27902902
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of cell associated vaccines against Marek's disease virus grown in a continuous cell line from chickens.
Geerligs H; Quanz S; Suurland B; Spijkers IE; Rodenberg J; Davelaar FG; Jongsma B; Kumar M
Vaccine; 2008 Oct; 26(44):5595-600. PubMed ID: 18706949
[TBL] [Abstract][Full Text] [Related]
3. Host genetic resistance to Marek's disease sustains protective efficacy of herpesvirus of turkey in both experimental and commercial lines of chickens.
Chang S; Xie Q; Dunn JR; Ernst CW; Song J; Zhang H
Vaccine; 2014 Apr; 32(16):1820-7. PubMed ID: 24530405
[TBL] [Abstract][Full Text] [Related]
4. A comparative evaluation of the protective efficacy of rMd5deltaMeq and CVI988/ Rispens against a vv+ strain of Marek's disease virus infection in a series of recombinant congenic strains of White Leghorn chickens.
Chang S; Ding Z; Dunn JR; Lee LF; Heidari M; Song J; Ernst CW; Zhang H
Avian Dis; 2011 Sep; 55(3):384-90. PubMed ID: 22017035
[TBL] [Abstract][Full Text] [Related]
5. Detection and differentiation of CVI988 (Rispens vaccine) from other serotype 1 Marek's disease viruses.
Gimeno IM; Dunn JR; Cortes AL; El-Gohary Ael-G; Silva RF
Avian Dis; 2014 Jun; 58(2):232-43. PubMed ID: 25055627
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of cell-associated vaccines against Marek's disease virus grown in QT35 cells or JBJ-1 cells.
Geerligs H; Spijkers I; Rodenberg J
Avian Dis; 2013 Jun; 57(2 Suppl):448-53. PubMed ID: 23901760
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of recombinant fowlpox vaccine protection against Marek's disease: its dependence on chicken line and B haplotype.
Lee LF; Bacon LD; Yoshida S; Yanagida N; Zhang HM; Witter RL
Avian Dis; 2004; 48(1):129-37. PubMed ID: 15077806
[TBL] [Abstract][Full Text] [Related]
8. Towards a mechanistic understanding of the synergistic response induced by bivalent Marek's disease vaccines to prevent lymphomas.
Umthong S; Dunn JR; Cheng HH
Vaccine; 2019 Oct; 37(43):6397-6404. PubMed ID: 31515142
[TBL] [Abstract][Full Text] [Related]
9. Characterization of four very virulent Argentinian strains of Marek's disease virus and the influence of one of those isolates on synergism between Marek's disease vaccine viruses.
Buscaglia C; Nervi P; Risso M
Avian Pathol; 2004 Apr; 33(2):190-5. PubMed ID: 15276986
[TBL] [Abstract][Full Text] [Related]
10. A toll-like receptor 3 ligand enhances protective effects of vaccination against Marek's disease virus and hinders tumor development in chickens.
Parvizi P; Mallick AI; Haq K; Haghighi HR; Orouji S; Thanthrige-Don N; St Paul M; Brisbin JT; Read LR; Behboudi S; Sharif S
Viral Immunol; 2012 Oct; 25(5):394-401. PubMed ID: 22857262
[TBL] [Abstract][Full Text] [Related]
11. Protective efficacy of a recombinant bacterial artificial chromosome clone of a very virulent Marek's disease virus containing a reticuloendotheliosis virus long terminal repeat.
Mays JK; Black-Pyrkosz A; Spatz S; Fadly AM; Dunn JR
Avian Pathol; 2016 Dec; 45(6):657-666. PubMed ID: 27258614
[TBL] [Abstract][Full Text] [Related]
12. A deletion in the glycoprotein L (gL) gene of U.S. Marek's disease virus (MDV) field strains is insufficient to confer increased pathogenicity to the bacterial artificial chromosome (BAC)-based strain, RB-1B.
Shaikh SA; Katneni UK; Dong H; Gaddamanugu S; Tavlarides-Hontz P; Jarosinski KW; Osterrieder N; Parcells MS
Avian Dis; 2013 Jun; 57(2 Suppl):509-18. PubMed ID: 23901769
[TBL] [Abstract][Full Text] [Related]
13. Recombinant Gallid herpesvirus 2 with interrupted meq genes confers safe and efficacious protection against virulent field strains.
Zhang Y; Liu C; Yan F; Liu A; Cheng Y; Li Z; Sun G; Lv H; Wang X
Vaccine; 2017 Aug; 35(36):4695-4701. PubMed ID: 28754487
[TBL] [Abstract][Full Text] [Related]
14. Vaccinal control of Marek's disease: current challenges, and future strategies to maximize protection.
Baigent SJ; Smith LP; Nair VK; Currie RJ
Vet Immunol Immunopathol; 2006 Jul; 112(1-2):78-86. PubMed ID: 16682084
[TBL] [Abstract][Full Text] [Related]
15. Protective efficacy of Marek's disease virus (MDV) CVI-988 CEF65 clone C against challenge infection with three very virulent MDV strains.
de Boer GF; Groenendal JE; Boerrigter HM; Kok GL; Pol JM
Avian Dis; 1986; 30(2):276-83. PubMed ID: 3015113
[TBL] [Abstract][Full Text] [Related]
16. Differential amplification of Marek's disease CVI988 vaccine and of wild-type isolates from organs of commercial chickens using single or duplexed probes in real-time PCR.
Davidson I; Natour-Altoury A; Raibstein I; Dahan Y
Avian Pathol; 2017 Dec; 46(6):610-614. PubMed ID: 28532188
[TBL] [Abstract][Full Text] [Related]
17. Protection provided by Rispens CVI988 vaccine against Marek's disease virus isolates of different pathotypes and early prediction of vaccine take and MD outcome.
Ralapanawe S; Walkden-Brown SW; Renz KG; Islam AF
Avian Pathol; 2016; 45(1):26-37. PubMed ID: 26503904
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of vaccine efficacy of recombinant Marek's disease virus vaccine lacking Meq oncogene in commercial chickens.
Lee LF; Kreager KS; Arango J; Paraguassu A; Beckman B; Zhang H; Fadly A; Lupiani B; Reddy SM
Vaccine; 2010 Feb; 28(5):1294-9. PubMed ID: 19941987
[TBL] [Abstract][Full Text] [Related]
19. A Common Live-Attenuated Avian Herpesvirus Vaccine Expresses a Very Potent Oncogene.
Conradie AM; Bertzbach LD; Bhandari N; Parcells M; Kaufer BB
mSphere; 2019 Oct; 4(5):. PubMed ID: 31597721
[TBL] [Abstract][Full Text] [Related]
20. Serotype 1 viruses modified by backpassage or insertional mutagenesis: approaching the threshold of vaccine efficacy in Marek's disease.
Witter RL; Kreager KS
Avian Dis; 2004 Dec; 48(4):768-82. PubMed ID: 15666858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
